It was my pleasure and an honor to be named one of ASCO's Featured Voices for this year's annual meeting. Over the course of the next few days I will be highlighting the research studies presented at the #ASCO20 Virtual Annual Meeting. I will share posters, oral abstracts and presentations on gynecologic oncology, survivorship, cancer disparities and the impact of COVID 19 on cancer patients . I will also share parts of ASCO President Skip Buris's address and the keynote address by author, physician and cancer survivor Dr David Fajgenbaum.
Since my Voice was active on Twitter I will share the tweets I wrote as well as ones I retweeted.
Today, I will begin with gynecologic cancer studies.
Surgery on Recurrence - Ovarian Cancer
Abstract 6000
Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). meetinglibrary.asco.org/record/185438/Final analysis of AGO DESKTOP III/ENGOT-ov 20#6000 Secondary cytoreductive surgery(SRC) in recurrent ovarian cancer (ROC) Dr DuBois— Dee Sparacio (@womenofteal) May 29, 2020
“OS benefit >12 mos for pts with complete resection (CR) compared to pts without surgery (median 60.7 vs. 46.2 mos) #gyncsm #ASCO20 #OVCA 1/2
Secondary CRS in ROC is back to the game, good selection of your patients & high quality surgery will significantly improve survival #gyncsm... Choose them wisely & aim for complete CRS... pic.twitter.com/148HpeCGml— خالد الوادي (@alwadikhaled) May 29, 2020
Abstract 6001
PFS was 18.1 m vs 13.6 m in favor of the surgery arm #gyncsm #ASCO20 #OVCA Dr R Zang#6001 phase III trial of secondary cytoreductive surgery (CSR) in later recurrent ovarian cancer: SOC1/SGOG-OV2— Dee Sparacio (@womenofteal) May 29, 2020
Select Patients(predicted R0 surgery)extension of PFS to start of first subsequent therapy (TFST) 1/2 pic.twitter.com/6Y4hFmO9g5
If you want to learn more head over to this YouTube video ( https://youtu.be/22UFGOGZ9lI ) featuring Dr Coleman's ASCO “Dissecting Out Improved Outcomes.” via #SGOatASCO.
PARP Inhibitors - Ovarian Cancer
Abstract 6002
#6002 Final overall survival (OS) results from SOLO2/ENGOT-ov21— Dee Sparacio (@womenofteal) May 29, 2020
Maintenance olaparib provided an improvement of 12.9 months in median OS vs placebo. #gyncsm #ASCO20 #OVCA Dr A Poveda pic.twitter.com/OYyEkPXy6E
Olaparib w/ Cediranib - Ovarian Cancer
Abstract 6003
This was an all oral non-platinum treatment trial. Cediranib is a tyrosine kinase inhibitor for VEGFR1,2,3. Protocol was amended to allow maintenance therapy.#6003 phase III comparing olaparib or combo cediranib and olaparib to std plat chemo in recurrent plat-sensitive #ovca Dr Lui "C+O demonstrated similar activity to SOC in relapsed plat-sensitive ovca but did not meet the primary endpoint of improved PFS" 1/2 #gyncsm #ASCO20— Dee Sparacio (@womenofteal) May 29, 2020
Folate receptor - Ovarian Cancer
Abstract 6004
Ovarian Cancer exhibits a folate receptor alpha (FRα). Adverse Events included diarrhea , blurred vision , nausea , and fatigue. Dr Gilbert presented.Ab 6004 Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), combo w/ bev in patients (pts) w/ platinum-agnostic ovarian cancer.— Dee Sparacio (@womenofteal) May 29, 2020
overall response rate (ORR) of 43%, high FRα expressing tumors ORR was 61% #gyncsm #ASCO20 #OVCA
Pembolizumab PD-1 - Ovarian Cancer
Abstract 6005
If you can learn more about these studies by watching this video of Dr. Banerjee’s presentation, “Stay Sharp on PARP and More.” #SGOatASCO https://youtu.be/ZTUyn8vPZ2Q6005 KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Pembro monotherapy Increased ORR & trend to higher OS with >PD-1 expression Median OS was 18.7 months overall, Dr Matolunis https://t.co/2eRjkNFc5K#gyncsm #ASCO20 #OVCA— Dee Sparacio (@womenofteal) May 29, 2020
Olaparib LIGHT Study - Ovarian Cancer
Abstract 6013
Poster 6013:Olaparib in pts with platinum-sensitive relapsed (PSR) #ovca by BRCA mutation (BRCAm) & homologous recombination deficiency (HRD) status: LIGHT study.— Dee Sparacio (@womenofteal) May 29, 2020
Similar Olaparib efficacy was seen in the gBRCAm and sBRCAm cohorts #gyncsm #ASCO20 1/2
In non-BRCAm patients - HRD + patients had longer median PFS and higher ORR than HRD- patients #gyncsm #ASCO20 #OVCA #goASCO20— Dee Sparacio (@womenofteal) May 29, 2020
2/2
Imaging with PARP inhibitor - Ovarian Cancer
Abstract 6014
BRCA1/ 2 Testing Ovarian Cancer#gyncsm #ASCO20 Abstr 6014 (Tjokrowidjaj, et al) has an important message as well:— Don S. Dizon MD 🇬🇺 (@drdonsdizon) May 29, 2020
For women with mBRCA on maintenance PARP for platinum-sensitive recurrent ovarian cancer:
CA125 PD correlates with PD by imaging (RECIST) BUT
PD imaging seen in 40% with a CA125 in nl range: pic.twitter.com/64nN6CdYcu
Niraparib and bevacizumab Ovarian CancerDespite guidelines dating back to 2008 that all ovarian cancer patients should have BRCA1/2 testing (either germline or somatic), #cancerlinq RWE shows that only 22.6% of ovarian patients actually received testing. Huge opportunity for incr. education. #ASCO20 #gyncsm pic.twitter.com/dn0U8B0BQz— Jamie Holloway, PhD (@jamienholloway) May 29, 2020
Abstract 6012
# 6012 Poster Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive #ovca —A randomized controlled chemotherapy-free study.#gyncsm #ASCO20 #OVCA— Dee Sparacio (@womenofteal) May 29, 2020
Immunotherapy Clear cell OCPFS demonstrates that the niraparib-bevacizumab combination had clinically and statistically meaningful results. Trial not powered for other endpoints Dr Mirza #gyncsm #ASCO20 #OVCA pic.twitter.com/xRCwkH9PLz— Dee Sparacio (@womenofteal) May 29, 2020
Abstract #302065
Interesting I/O poster by Klein et al. Abstr #302065
Volunteers: All with rare gyn cancers (n=43)
Intervention: Ipi+Nivo
Comparator: NA
Outcome: ORR 28%
*Clear cell cancer (n=6): ORR 33% (1 CR seen)#gyncsm #ASCO20
Volunteers: All with rare gyn cancers (n=43)
Intervention: Ipi+Nivo
Comparator: NA
Outcome: ORR 28%
*Clear cell cancer (n=6): ORR 33% (1 CR seen)#gyncsm #ASCO20
— Don S. Dizon MD 🇬🇺 (@drdonsdizon) May 29, 2020
Cervical Cancer
Abstract 6007
STARS study of adjuvant RT v sequential (SCRT) v concurrent (CCRT) chemoRT in IB1-IIA2 cervical ca #ASCO2020 #gyncsm #OncoAlert— Nat Lester-Coll, MD (@DrLesterColl) May 29, 2020
1° endpoint: DFS
👉⬆️LN+ SCRT/CCRT,⬆️compliance RT alone
👉SCRT⬆️DFS, DRFS, even vCCRT! Most in HR subgroup
👉SCRT⬆️OS vRT alone
👉❌diff long-term QoL pic.twitter.com/yKC5joE1Sh
For recurrence, the main advantage for sequential chemoRT was in reducing the risk of distant recurrence. 4-year local recurrence rates <10% for intermediate risk, 10-15% for high risk in all arms.— Matthew Katz, MD (@subatomicdoc) May 30, 2020
Gr3 toxicity in sequential CRT arm< concurrent CRT #ASCO20 #gyncsm
G5/
There are many more abstracts and posters related to gyn cancers available in the ASCO Meeting Library.
Dee
Every Day is a Blessing!
No comments:
Post a Comment